- Home
- FSLR vs GH Comparison
FSLR vs GH Comparison
Compare FSLR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSLR | GH |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 20.6B |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FSLR | GH |
|---|---|---|
| Price | $225.56 | $157.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 19 |
| Target Price | ★ $236.42 | $119.79 |
| AVG Volume (30 Days) | ★ 2.5M | 1.9M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.22 | 6.74 |
| EPS | ★ 7.14 | N/A |
| Revenue | ★ $5,219,376,000.00 | $982,021,000.00 |
| Revenue This Year | $1.43 | $33.30 |
| Revenue Next Year | $16.77 | $28.27 |
| P/E Ratio | $31.31 | ★ N/A |
| Revenue Growth | 24.09 | ★ 32.88 |
| 52 Week Low | $182.99 | $53.40 |
| 52 Week High | $320.95 | $176.58 |
Technical Indicators
Market Signals| Indicator | FSLR | GH |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 51.09 |
| Support Level | $217.35 | $152.64 |
| Resistance Level | $248.93 | $175.33 |
| Average True Range (ATR) | 14.63 | 7.48 |
| MACD | 1.40 | -0.35 |
| Stochastic Oscillator | 38.94 | 45.32 |
Price Performance
Historical ComparisonAbout FSLR First Solar Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.